This is a serious lung problem that can happen after a stem cell transplant or a lung transplant. It means the tiny air passages in the lungs become scarred and blocked, making it hard to breathe. It's a complication, meaning it's a potential side effect of the treatment.
Every report comes from a Lived member, sent anonymously.
Have you tried Z-Pak (Azithromycin) for Bronchiolitis Obliterans Syndrome?
Bronchiolitis obliterans syndrome (BOS) is a long-term lung complication in which the smallest airways, the bronchioles, become inflamed, scarred and narrowed. Air gets in but has trouble getting out, so breathing out becomes harder and lung function gradually falls. People often notice shortness of breath with activity, a dry or persistent cough, wheezing or tiredness, though early BOS can cause no symptoms at all. The term is used for two groups of people. After a lung transplant, BOS is the most common form of chronic rejection, now grouped under chronic lung allograft dysfunction (CLAD): the recipient's immune system slowly damages the airways of the donor lung. After an allogeneic stem cell or bone marrow transplant (one using donor cells), BOS is a lung form of chronic graft-versus-host disease (GVHD), in which the donor's immune cells attack the recipient's own tissues. In that setting it usually comes with GVHD affecting other parts of the body, such as the skin, mouth or eyes. The same kind of airway scarring can occasionally follow inhaled chemical exposures (sometimes called popcorn lung) or a severe childhood infection, but those are different situations from the transplant-related syndrome described here.
After a lung transplant, BOS reflects the immune system's long-term response to the donor lung, added to injuries that inflame the airways. Factors linked to higher risk include earlier episodes of acute rejection or antibody-mediated rejection, injury to the new lung around the time of surgery, acid or non-acid reflux from the stomach that reaches the lungs, and certain infections, including cytomegalovirus (CMV), common respiratory viruses, Pseudomonas bacteria and Aspergillus mold. Air pollution, tobacco smoke and missed or insufficient anti-rejection medicine also add to risk. After a stem cell transplant, BOS usually appears between about three months and two years later and is closely tied to chronic GVHD elsewhere in the body. Having had acute GVHD, more intensive pre-transplant conditioning treatment, and transplants using blood-derived stem cells are among the factors associated with higher risk. These are associations, not certainties. Many people with risk factors never develop BOS, and it can occur in people who did everything their team asked.
The key test is spirometry, a breathing test that measures how much air you can blow out. The most important number is the forced expiratory volume in one second (FEV1): the amount of air pushed out in the first second of a hard breath. In BOS, FEV1 falls because the narrowed airways slow the outflow of air. After a lung transplant, the team sets a personal baseline from the best FEV1 readings in the months after surgery. Chronic lung allograft dysfunction is diagnosed when FEV1 stays at least 20% below that baseline for more than three months and no other cause explains it; the BOS form is identified by an obstructive pattern, meaning air is trapped rather than the lung shrinking. A drop of about 10% is usually enough to start investigating. The severity stage is then based on how far FEV1 has fallen from baseline. After a stem cell transplant, doctors look for a similar pattern of blocked airflow on breathing tests, usually alongside other signs of chronic GVHD. Because lung tests are often done less frequently after this kind of transplant, BOS can be found late. In both settings, BOS is a diagnosis made after ruling out other explanations, especially infection and, after lung transplant, acute rejection. This may involve a chest computed tomography (CT) scan (taken while breathing in and out, which can show trapped air), blood tests, and bronchoscopy, in which a thin tube is passed into the airways to take samples. Some lung transplant recipients also check their FEV1 at home with a handheld spirometer, which can catch a drop early but does not replace clinic testing.
Treatment aims to stop or slow the loss of lung function. Damaged airways do not usually heal, so catching BOS early and stabilizing it matters more than restoring what is lost. No treatment has been proven to reliably reverse it, and responses vary widely from person to person. After a lung transplant, the team first treats anything that may be adding to the damage, such as infection, acute rejection or reflux (sometimes with anti-reflux surgery), and reviews the anti-rejection regimen, for example switching from cyclosporine to tacrolimus. Azithromycin, an antibiotic used long term for its anti-inflammatory effect, improves lung function in roughly a third to half of people with BOS; many centers also start it soon after transplant to lower the risk of BOS developing. Its main drawbacks are stomach upset and, with long-term use, a possible effect on hearing. Montelukast, an anti-inflammatory asthma pill, may help in early BOS. If lung function keeps falling, options include extracorporeal photopheresis (ECP), in which blood is drawn, treated with light to calm the immune response and returned over repeated sessions, or radiation aimed at the lymph nodes. These have shown slowing of decline in some studies, but the evidence is limited and ECP can be costly and time-consuming. After a stem cell transplant, BOS is treated as part of chronic GVHD. A common first approach combines an inhaled steroid (fluticasone), azithromycin and montelukast (together called FAM), often with a short course of steroid tablets, added to the person's GVHD treatment. Long-term high-dose steroids are not thought to help the lungs themselves. For chronic GVHD that has not responded to earlier treatment, medicines such as ruxolitinib (Jakafi) and belumosudil (Rezurock), both targeted immune-modifying pills, are approved in the US for people 12 and older, though their benefit for BOS specifically is not well established. Clinical trials are an important option. In both groups, pulmonary rehabilitation, protection against infections, good nutrition and oxygen when needed support daily function. When BOS becomes severe despite treatment, a lung transplant (or, after a lung transplant, a second one) may be considered for carefully selected people.
BOS is usually a long-term condition, and its course is hard to predict. Some people lose lung function steadily over months or years and eventually develop respiratory failure, while others stabilize and stay at a similar level for a long time. After a stem cell transplant, decline can sometimes be rapid, especially in the first few months. After a lung transplant, BOS is the main reason transplanted lungs fail over time; chronic lung allograft dysfunction develops in roughly a third to half of recipients within five years. Daily life often revolves around monitoring and treatment: regular breathing tests, sometimes home spirometry, frequent clinic visits and a long-term medicine routine with careful attention to infection. Shortness of breath may limit exercise, work and travel, and fatigue is common. Pulmonary rehabilitation can help people stay as active as possible. Living with the uncertainty of a complication after an already demanding transplant can be emotionally hard, and transplant social workers, patient groups and support for caregivers can make a difference.
Keep every scheduled breathing test and transplant follow-up, even when you feel well, since BOS can start without symptoms and early treatment gives the best chance of stabilizing lung function. Contact your transplant team promptly if you notice new or worsening shortness of breath, a new or persistent cough, unusual tiredness or wheezing, or if your home spirometry readings drop. These can signal BOS but can also be infection or acute rejection, which are treated differently and can often be reversed, so prompt testing matters.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Bronchiolitis Obliterans Syndrome is like, what's helped you, or ask the community a question.